Study objectives
1. To characterize the efficacy of reparixin in ameliorating lung injury and systemic
inflammation and expediting clinical recovery and liberation from mechanical ventilation
in adult patients with moderate to severe ARDS (PaO2/FIO2 ratio ≤ 200).
2. To evaluate the safety of reparixin vs. placebo in patients enrolled in the study.